OMNI 360 Wealth Inc. Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

OMNI 360 Wealth Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,610 shares of the company’s stock after purchasing an additional 212 shares during the period. OMNI 360 Wealth Inc.’s holdings in Johnson & Johnson were worth $571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in JNJ. Kennedy Capital Management LLC lifted its holdings in Johnson & Johnson by 18.6% in the third quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock valued at $3,189,000 after acquiring an additional 3,206 shares during the last quarter. Ramirez Asset Management Inc. acquired a new position in Johnson & Johnson in the third quarter valued at approximately $1,180,000. Stonebridge Capital Advisors LLC lifted its holdings in Johnson & Johnson by 4.9% in the third quarter. Stonebridge Capital Advisors LLC now owns 90,302 shares of the company’s stock valued at $14,065,000 after acquiring an additional 4,247 shares during the last quarter. Pacific Center for Financial Services lifted its stake in Johnson & Johnson by 107.1% during the third quarter. Pacific Center for Financial Services now owns 1,553 shares of the company’s stock worth $242,000 after purchasing an additional 803 shares in the last quarter. Finally, Studio Investment Management LLC lifted its stake in Johnson & Johnson by 7.8% during the third quarter. Studio Investment Management LLC now owns 26,356 shares of the company’s stock worth $4,105,000 after purchasing an additional 1,909 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. The Goldman Sachs Group started coverage on Johnson & Johnson in a research note on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE JNJ opened at $145.69 on Friday. The business has a 50-day moving average of $147.96 and a two-hundred day moving average of $153.85. The company has a market capitalization of $350.63 billion, a price-to-earnings ratio of 9.08, a price-to-earnings-growth ratio of 2.42 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the company posted $2.68 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.40%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.